Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sysmex Corporation (6869.T)
Kobe, JP
Sysmex Corporation, headquartered in Kobe, Japan, and established in 1968 (originally known as TOA Medical Electronics Co., Ltd. until its rebranding in October 1998), specializes in the development, manufacturing, and global distribution of advanced diagnostic instrumentation, chemical reagents, and associated software. Its comprehensive product portfolio addresses various diagnostic needs. In hematology, it offers instruments for both three-part and five-part white blood cell differentiation, alongside efficient transport systems designed for high-volume laboratory testing. For urinalysis, the company provides systems capable of analyzing urine formed sediment. Its offerings extend to automated immunochemistry systems, which are adept at performing assays with minute sample quantities, complemented by reagents for detecting infectious diseases and tumor markers. Sysmex also manufactures flow cytometers, crucial for the analysis involved in diagnosing conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Beyond these core areas, the company is deeply involved in oncology diagnostics, developing systems for detecting cancer lymph node metastasis and cancer genome profiling, as well as offering cytogenetic testing and specialized lab assay services. Sysmex also contributes to digital medicine through the development and sale of software for diagnostic information systems, alongside the creation, operation, and maintenance of IT solutions, platforms, and applications in this field. Its activities further encompass the development and sale of nucleic acid analogs, the full lifecycle management (marketing, development, design, manufacture, sale, and after-sales support) of medical robots, and the distribution and post-sales support for medical devices and reagents used in biotechnology, medical technology, and molecular cell analysis. Sysmex serves a diverse client base, including national, public, and private hospitals, universities, research institutes, and other medical facilities. With a robust international presence, the company exports its products to approximately 190 countries worldwide. Demonstrating its commitment to innovation, Sysmex Corporation maintains a strategic alliance with QIAGEN N.V. for the collaborative development and commercialization of cancer companion diagnostics utilizing Plasma-Safe-SeqS technology.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.09% | +1.31% | -6.09% | +5.43% | -11.80% | -12.06% | -44.45% | -58.24% | -61.63% | -48.36% | +1,241.18% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 4 | 0 |
| Hold | 8 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%-1.7% Q1'26: -2.1% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-33.9% Q1'26: -84.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+10.4% Q1'26: +9.4% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+12.4% Q1'26: +10.9% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+9.1% ★ Q1'26: +12.3% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.1% ★ Q1'26: -0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.65× Q1'26: 0.66× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 15 Rev. Ana. 4 EPS Ana. |
Mar 2027 8 Rev. Ana. 10 EPS Ana. |
Mar 2028 14 Rev. Ana. 14 EPS Ana. |
Mar 2029 9 Rev. Ana. 8 EPS Ana. |
Mar 2030 4 Rev. Ana. 3 EPS Ana. |
Mar 2031 3 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
221.38B
est: 217.63B (+1.7%)
|
252.62B
est: 258.02B (-2.1%)
|
249.90B
est: 252.35B (-1.0%)
|
281.94B
est: 280.09B (+0.7%)
|
293.51B
est: 293.70B (-0.1%)
|
301.98B
est: 305.02B (-1.0%)
|
305.07B
est: 301.00B (+1.4%)
|
363.78B
est: 357.45B (+1.8%)
|
410.50B
est: 417.28B (-1.6%)
|
461.51B
est: 478.11B (-3.5%)
|
508.64B
est: 513.14B (-0.9%)
|
498.17B
489.55B – 532.84B
-2.9% YoY
|
533.40B
523.04B – 540.96B
+7.1% YoY
|
562.80B
527.73B – 594.14B
+5.5% YoY
|
588.97B
586.81B – 591.12B
+4.6% YoY
|
625.38B
599.40B – 647.65B
+6.2% YoY
|
639.70B
613.12B – 662.48B
+2.3% YoY
|
| EBITDA |
57.36B
est: 54.91B (+4.5%)
|
72.82B
est: 65.10B (+11.9%)
|
63.20B
est: 63.67B (-0.7%)
|
74.59B
est: 70.67B (+5.5%)
|
76.64B
est: 74.11B (+3.4%)
|
78.46B
est: 76.96B (+1.9%)
|
74.58B
est: 75.95B (-1.8%)
|
97.00B
est: 90.19B (+7.5%)
|
104.46B
est: 105.29B (-0.8%)
|
113.19B
est: 118.25B (-4.3%)
|
128.71B
est: 126.91B (+1.4%)
|
123.21B
121.08B – 131.78B
-2.9% YoY
|
131.92B
129.36B – 133.79B
+7.1% YoY
|
139.19B
130.52B – 146.94B
+5.5% YoY
|
145.66B
145.13B – 146.20B
+4.6% YoY
|
154.67B
148.24B – 160.18B
+6.2% YoY
|
158.21B
151.64B – 163.84B
+2.3% YoY
|
| EBIT |
44.41B
est: 37.91B (+17.2%)
|
60.71B
est: 44.94B (+35.1%)
|
50.82B
est: 43.95B (+15.6%)
|
59.95B
est: 48.79B (+22.9%)
|
60.80B
est: 51.16B (+18.8%)
|
54.50B
est: 53.13B (+2.6%)
|
49.17B
est: 52.43B (-6.2%)
|
69.57B
est: 62.26B (+11.7%)
|
72.65B
est: 72.68B (0.0%)
|
77.30B
est: 79.97B (-3.3%)
|
89.68B
est: 85.83B (+4.5%)
|
83.33B
81.89B – 89.13B
-2.9% YoY
|
89.22B
87.49B – 90.49B
+7.1% YoY
|
94.14B
88.27B – 99.38B
+5.5% YoY
|
98.52B
98.16B – 98.88B
+4.6% YoY
|
104.61B
100.26B – 108.33B
+6.2% YoY
|
107.00B
102.56B – 110.81B
+2.3% YoY
|
| Net Income |
26.64B
est: 27.73B (-3.9%)
|
39.28B
est: 35.14B (+11.8%)
|
40.64B
est: 42.91B (-5.3%)
|
39.22B
est: 41.80B (-6.2%)
|
41.22B
est: 39.20B (+5.2%)
|
34.88B
est: 37.83B (-7.8%)
|
31.90B
est: 33.07B (-3.5%)
|
44.09B
est: 44.18B (-0.2%)
|
45.78B
est: 50.12B (-8.6%)
|
49.64B
est: 52.05B (-4.6%)
|
53.67B
est: 57.81B (-7.2%)
|
39.20B
37.69B – 40.70B
-32.2% YoY
|
42.93B
39.20B – 51.07B
+9.5% YoY
|
52.27B
41.35B – 74.40B
+21.8% YoY
|
58.17B
45.27B – 79.69B
+11.3% YoY
|
62.68B
59.29B – 65.58B
+7.7% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
63.28B
est: 60.25B (+5.0%)
|
74.57B
est: 71.43B (+4.4%)
|
75.40B
est: 69.86B (+7.9%)
|
82.25B
est: 77.54B (+6.1%)
|
81.23B
est: 81.31B (-0.1%)
|
83.55B
est: 84.44B (-1.1%)
|
82.62B
est: 83.33B (-0.9%)
|
94.24B
est: 98.96B (-4.8%)
|
112.37B
est: 115.52B (-2.7%)
|
133.80B
est: 138.46B (-3.4%)
|
150.85B
est: 148.60B (+1.5%)
|
144.27B
141.77B – 154.31B
-2.9% YoY
|
154.47B
151.47B – 156.66B
+7.1% YoY
|
162.98B
152.83B – 172.06B
+5.5% YoY
|
170.56B
169.94B – 171.18B
+4.6% YoY
|
181.11B
173.58B – 187.55B
+6.2% YoY
|
185.25B
177.56B – 191.85B
+2.3% YoY
|
| EPS |
42.83
est: 44.45 (-3.6%)
|
63.03
est: 56.34 (+11.9%)
|
65.10
est: 68.80 (-5.4%)
|
62.76
est: 67.01 (-6.3%)
|
65.87
est: 62.85 (+4.8%)
|
55.70
est: 60.65 (-8.2%)
|
50.91
est: 53.01 (-4.0%)
|
70.29
est: 70.84 (-0.8%)
|
72.94
est: 80.10 (-8.9%)
|
79.27
est: 83.26 (-4.8%)
|
86.07
est: 93.11 (-7.6%)
|
64.06
60.48 – 65.31
-31.2% YoY
|
71.86
62.90 – 81.94
+12.2% YoY
|
82.25
66.35 – 119.38
+14.5% YoY
|
89.28
72.64 – 127.86
+8.5% YoY
|
100.57
95.14 – 105.22
+12.6% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hisashi Ietsugu | Chairman of the Board & Group Chief Executive Officer | 226M | male |
| Kaoru Asano | Representative Director | 211M | male |
| Iwane Matsui | President & Representative Director | 108M | male |
| Kenji Tachibana | Senior Executive Officer, Senior MD & Director | 100M | male |
| Reiko Watanabe | Executive Officer & Executive Vice President of Medical Affairs Div. | — | — |
| Takaaki Nagai | Executive Officer & Executive Vice President of System Engineering Div. | — | — |
| Takashi Hatakeda | Executive Officer & Executive VP of Corporate Communication Div. | — | — |
| Takashi Ono | Managing Executive Officer & Director | — | male |
| Tomokazu Yoshida | Managing Executive Officer, Chief Technology Officer & Director | — | male |
| Frank Buescher | Senior Executive Officer | — | male |
| Zuo Hui Peng | Executive Officer | — | male |
| Kensuke Iizuka | Managing Executive Officer & CFO | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6869.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
